GLP1R and Alzheimer disease: Besides, a suggestive association between genetic variation in the GLP-1 analogue target and lower risk of AD was observed across different MR methods (Figure 3 and eTable 4, links.lww.com/WNL/C91, IVW: OR = 0.32, 95% CI 0.13–0.79, p = 0.014; weighted median: OR = 0.34, 95% CI 0.11–1.07, p = 0.066; MR-Egger: OR = 0.35, 95% CI 0.05–2.52, p = 0.49).